This document outlines a research protocol for a scoping review aimed at mapping the complex landscape of treatments for lung cancer patients who have hit a "therapeutic wall" due to drug resistance.
TL;DR
Researchers are launching a comprehensive scoping review to synthesize over 15 years of clinical data on how to treat advanced lung cancer after standard targeted therapies (TKIs) fail. By mapping emerging treatments like fourth-generation inhibitors and antibody-drug conjugates against specific resistance mechanisms, they aim to provide a roadmap for the next generation of precision oncology.
What Problem Does This Paper Address?
For patients with Non-Small Cell Lung Cancer (NSCLC) harboring EGFR mutations, Tyrosine Kinase Inhibitors (TKIs) like osimertinib have been life-changing. However, cancer is an evolutionary moving target. Almost all patients eventually develop resistance—typically within 9 to 12 months—as the tumor acquires new mutations (like C797S) or activates "bypass" signaling pathways to survive.
While several new strategies exist—including fourth-generation TKIs, combination therapies, and Antibody-Drug Conjugates (ADCs)—there is a lack of high-quality, systematic evidence synthesis to guide clinicians on which path to take once the first line of defense fails. This is particularly urgent in Asia, where EGFR mutations are significantly more prevalent than in Western populations.
Methods
As this is a protocol, it defines the rigorous methodology the authors will use to conduct their review:
- Search Strategy: The team will perform an exhaustive search of four major medical databases (PubMed, Embase, Web of Science, and Cochrane) using complex Boolean strings designed to capture every clinical trial related to EGFR-mutant NSCLC resistance since 2009.
- Screening Process: Using the Rayyan platform, two independent reviewers will screen titles and abstracts, followed by a full-text review to ensure only relevant clinical trials (RCTs, non-RCTs, and single-arm trials) are included.
- Data Extraction: The review will focus on three pillars:
- Regimens: Summarizing efficacy (Survival rates, response duration) and safety.
- Prior History: Tracking which specific TKIs patients failed previously.
- Mechanisms: Linking treatments to the specific biological resistance mechanisms they are designed to overcome.
Datasets
Because this is a scoping review of existing literature, the "datasets" are the collective results of clinical trials published globally between January 2009 and the present. The authors will utilize:
- Primary Databases: PubMed, Embase, Web of Science, and Cochrane Library.
- Grey Literature: Important conference abstracts may be included as "expert supplemented literature" to capture the most cutting-edge, yet-to-be-published data.
Key Insights and Ideas
- The Shift to Multi-Targeting: The protocol highlights a move away from simple monotherapy. It specifically looks for data on bispecific antibodies (targeting both EGFR and c-MET) and ADCs (targeting Trop2 or HER3), which act like "Trojan horses" to deliver chemotherapy directly to cancer cells.
- Mechanism-Based Precision: Rather than a "one size fits all" approach to resistance, the authors emphasize the need to categorize treatments by the specific resistance mechanism they target (e.g., on-target vs. bypass pathway inhibition).
- Addressing the "Modest" Standard: The authors acknowledge that while chemotherapy remains the fallback, its results are often modest. This review seeks to identify which novel combinations (e.g., TKIs plus anti-angiogenic agents) actually move the needle on patient survival.
Key Results
Note: As this is a protocol, quantitative results are not yet available.
The expected output will be a comprehensive summary of:
- Overall Survival (OS) and Progression-Free Survival (PFS) across different second- and third-line regimens.
- Intracranial Progression-Free Survival (iPFS): A critical metric, as lung cancer frequently spreads to the brain.
- Safety Profiles: A comparison of Total Adverse Events (AE) across these emerging therapies.
Limitations and Future Work
- Language Bias: The search is restricted to English-language literature. Given the high prevalence of these mutations in China and Japan, some local-language data might be missed.
- Scoping vs. Meta-analysis: As a scoping review, this study aims to map the evidence rather than provide a statistically pooled "final answer" on which drug is best.
- Future Directions: The authors expect their findings to highlight "promising directions" for future clinical trials and help Chinese medical experts develop more effective treatment guidelines for a patient population with a high unmet medical need.
Summary updated